Cancer Cell

Article	Citations
Accelerated approvals: Early-phase success or premature authorization?	1720
KIT as a therapeutic target in neuroendocrine prostate cancer	799
Olfactory neuroblastoma mimics molecular heterogeneity and lineage trajectories of small-cell lung cancer	531
TAMing immunity through an unexpected source	525
Diet-microbiome interactions in cancer	494
Efficacy of booster doses in augmenting waning immune responses to COVID-19 vaccine in patients with cancer	384
KMT2D deficiency drives lung squamous cell carcinoma and hypersensitivity to RTK-RAS inhibition	374
Dynamic circulating tumor DNA during chemoradiotherapy predicts clinical outcomes for locally advanced non-small cell lung cancer patients	367
Hand in hand to successful immunotherapy: CD8+ T cells and M1-like macrophages swap the baton	358
Characterization of the generic mutant p53-rescue compounds in a broad range of assays	351
EGFR-activated myofibroblasts promote metastasis of pancreatic cancer	324
Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations	302
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas	297
Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer	291
Tissue factor is a critical regulator of radiation therapy-induced glioblastoma remodeling	280
Spatial profiling technologies illuminate the tumor microenvironment	275
Enhanced SARS-CoV-2 breakthrough infections in patients with hematologic and solid cancers due to Omicron	274
T cell dynamism and immune-related adverse events	273
Cancer vaccines	270
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer	256
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma	247
B cell heterogeneity in cancer comes of age	246
T-Lymphoblastic Lymphoma Cells Express High Levels of BCL2, S1P1, and ICAM1, Leading to a Blockade of Tumor Cell Intravasation	242
Bacteria in metastatic sites: Unveiling hidden players in cancer progression	239
A holistic view of cancer	230

The aging lung microenvironment awakens melanoma metastases	230
Simultaneous targeting of TGF-β/PD-L1 synergizes with radiotherapy by reprogramming the tumor microenvironment to overcome immune evasion	229
Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target	226
Intratumoral immune triads are required for immunotherapy-mediated elimination of solid tumors	224
Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses	221
Apolipoprotein E induces pathogenic senescent-like myeloid cells in prostate cancer	220
Targeting P4HA1 promotes CD8+ T cell progenitor expansion toward immune memory and systemic anti-tumor immunity	216
High endothelial venules in cancer: Regulation, function, and therapeutic implication	215
Elucidating acquired PARP inhibitor resistance in advanced prostate cancer	215
Spatiotemporal single-cell analysis decodes cellular dynamics underlying different responses to immunotherapy in colorectal cancer	213
Challenges in neoantigen-directed therapeutics	213
Antiandrogen treatment induces stromal cell reprogramming to promote castration resistance in prostate cancer	212
Multiomic analysis reveals conservation of cancer-associated fibroblast phenotypes across species and tissue of origin	209
Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments	194
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer	193
Tumor organoid-originated biomarkers predict immune response to PD-1 blockade	192
Circular RMST cooperates with lineage-driving transcription factors to govern neuroendocrine transdifferentiation	191
Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics	189
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts	188
Tumor-directed dysregulation of erythroid progenitors drives immunosuppressive myeloid cells	188
The one-two punch: TIM-3 blockade targets immune and tumor cells to knock out pediatric brain tumors	184
Are we ready to look beyond plasma cells in assessing high-risk smoldering myeloma?	183
Immunosensitivity cuts across mismatch repair status in colorectal cancer	183
A genetic portrait of metastatic seeds in lung adenocarcinoma	182
Revisiting TNM staging for EBV-related nasopharyngeal carcinoma	182
Lymphocyte networks are dynamic cellular communities in the immunoregulatory landscape of lung adenocarcinoma	182
Challenges and opportunities for modeling aging and cancer	179
Gut microbes promote chemoradiotherapy resistance via metabolic cross-feeding	178
Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy	175
Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification	175
Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy	174
Prior anti-CTLA-4 therapy impacts molecular characteristics associated with anti-PD-1 response in advanced melanoma	172
Multi-omic profiling of follicular lymphoma reveals changes in tissue architecture and enhanced stromal remodeling in high-risk patients	169
Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population	165
Hypoxia inducible factor-1α drives cancer resistance to cuproptosis	163
Mammalian SWI/SNF complex activity regulates POU2F3 and constitutes a targetable dependency in small cell lung cancer	154
Temporal evolution reveals bifurcated lineages in aggressive neuroendocrine small cell prostate cancer trans-differentiation	147
Single-cell analysis defines a pancreatic fibroblast lineage that supports anti-tumor immunity	146
Inflammatory fibroblasts mediate resistance to neoadjuvant therapy in rectal cancer	144
Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma	143
Dissecting bulk transcriptomes of diffuse large B cell lymphoma	143
Unbiased Combinatorial Screening Identifies a Bispecific IgG1 that Potently Inhibits HER3 Signaling via HER2-Guided Ligand Blockade	141
ILC3 plasticity in microbiome-mediated tumor progression and immunotherapy	140
Recognition of observer effect is required for rigor and reproducibility of preclinical animal studies	139
Single-cell multi-stage spatial evolutional map of esophageal carcinogenesis	139
Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers	137
A path to translation: How 3D patient tumor avatars enable next generation precision oncology	136
Adoptive cell therapy with tumor-specific Th9 cells induces viral mimicry to eliminate antigen-loss-variant tumor cells	136
Tumor-infiltrating lymphocytes: A new hope	135
Integrated proteogenomic characterization of glioblastoma evolution	133

The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma	132
Response-based molecular subtyping—emergence of the third generation of breast cancer subtypes	131
Tumor-intrinsic SIRPA promotes sensitivity to checkpoint inhibition immunotherapy in melanoma	130
Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness	129
Midkine as a driver of age-related changes and increase in mammary tumorigenesis	129
Tumor-resident Lactobacillus iners confer chemoradiation resistance through lactate-induced metabolic rewiring	128
Hepatobiliary tumor organoids for personalized medicine: a multicenter view on establishment, limitations, and future directions	126
Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD	124
Chronic stress increases metastasis via neutrophil-mediated changes to the microenvironment	123
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1	123
MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells	120
Immune determinants of the pre-metastatic niche	119
Risk factors for poor humoral response to primary and booster SARS-CoV-2 vaccination in hematologic and oncological outpatients—COVIDOUT study	118
Taxanes directly induce T cell cytotoxic extracellular vesicles to eradicate tumor cells	117
Multiplex computational pathology for treatment response prediction	116
Tumors on different wavelengths	114
GDF15 research from bench to bedside	113
Firing up neutrophil anti-tumor immunity with cocktails	112
Precise patient stratification in esophageal cancer: Biomarkers for immunochemotherapy	111
New horizons at the interface of artificial intelligence and translational cancer research	110
The winner takes it all: Competition drives clonal selection in gliomagenesis	110
A circular RNA in neuroendocrine carcinomas	110
Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial	110
Exercise-induced engagement of the IL-15/IL-15Rα axis promotes anti-tumor immunity in pancreatic cancer	107
T cell immune deficiency rather than chromosome instability predisposes patients with short telomere syndromes to squamous cancers	107
JUPITER-06 establishes immune checkpoint inhibitors as essential first-line drugs for the treatment of advanced esophageal squamous cell carcinoma	107
Progenitor-like exhausted SPRY1+CD8+ T cells potentiate responsiveness to neoadjuvant PD-1 blockade in esophageal squamous cell carcinoma	106
Increased glucose metabolism in TAMs fuels O-GlcNAcylation of lysosomal Cathepsin B to promote cancer metastasis and chemoresistance	105
Proteogenomic data and resources for pan-cancer analysis	105
Distinct spatiotemporal dynamics of CD8+ T cell-derived cytokines in the tumor microenvironment	105
Promotion of cholangiocarcinoma growth by diverse cancer-associated fibroblast subpopulations	101
Immunosequencing identifies signatures of T cell responses for early detection of nasopharyngeal carcinoma	101
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma	100
Integrated single cell analysis reveals co-evolution of malignant B cells and tumor micro-environment in transformed follicular lymphoma	100
GD2-CAR T cells in patients with osteosarcoma and neuroblastoma—it’s not only the T cells that matter	100
The promise and peril of KRAS G12C inhibitors	99
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer	99
Lactobacillus reuteri—an old acquaintance takes on a new task in colorectal tumor surveillance	98
An immunogenic and oncogenic feature-based classification for chemotherapy plus PD-1 blockade in advanced esophageal squamous cell carcinoma	97
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia	97
Enhanced but variant-dependent serological and cellular immune responses to third-dose BNT162b2 vaccination in patients with multiple myeloma	97
Intratumoral CD8+ T cells with a tissue-resident memory phenotype mediate local immunity and immune checkpoint responses in breast cancer	96
Gut microbiota-mediated nucleotide synthesis attenuates the response to neoadjuvant chemoradiotherapy in rectal cancer	96
Spatial transcriptomics reveals tryptophan metabolism restricting maturation of intratumoral tertiary lymphoid structures	96
CD8+ T cells and fatty acids orchestrate tumor ferroptosis and immunity via ACSL4	95
Integrative plasma and fecal metabolomics identify functional metabolites in adenoma-colorectal cancer progression and as early diagnostic biomarkers	95
Tumor heterogeneity	95
Single-cell dissection of cellular components and interactions shaping the tumor immune phenotypes in ovarian cancer	94
From intestinal metaplasia to gastric cancer: Witnessing the rise of evil over time and space	94
Getting a handle on KRAS inhibitor resistance with hapten-mediated anti-tumor immunity	92
PD-1 blockade is a promising therapeutic addition to neoadjuvant chemoradiation in locally advanced rectal cancer	92
Bacteria and fungi: The counteracting modulators of immune responses to radiation therapy in cancer	91
Plasma cell and cancer stem cell crosstalk in glioblastoma	91
Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers	90
Stromal barriers to the abscopal effect	90
Horizontal mitochondrial transfer in cancer biology: Potential clinical relevance	90
STAG2 mutations alter CTCF-anchored loop extrusion, reduce cis-regulatory interactions and EWSR1-FLI1 activity in Ewing sarcoma	89
High-frequency temperature monitoring for early detection of febrile adverse events in patients with cancer	89
Seed or soil: Tracing the immune subsets in metastatic tumors	89
Interactions between cancer cells and immune cells drive transitions to mesenchymal-like states in glioblastoma	88
Tumor microbiome links cellular programs and immunity in pancreatic cancer	86
High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer	85
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells	85
Glioblastoma induces the recruitment and differentiation of dendritic-like “hybrid” neutrophils from skull bone marrow	84
Isocitrate dehydrogenase 1 primes group-3 medulloblastomas for cuproptosis	84
Adiponectin reduces immune checkpoint inhibitor-induced inflammation without blocking anti-tumor immunity	83
Squamous cell cancers of the aero-upper digestive tract: A unified perspective on biology, genetics, and therapy	83
Stromal lipid species dictate melanoma metastasis and tropism	83
Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers	83
Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NECTIN2-TIGIT axis as a target for immunotherapy	82
Immunogenicity of a heterologous COVID-19 vaccine after failed vaccination in a lymphoma patient	81
Combining personalized neoantigen vaccination with chemotherapy and anti-PD-1 to treat NSCLC	81
Oncolytic virotherapy: Potentially a game-changing tumor treatment	81
Architecture sets the path: Breast cancer subtypes differently shape the early brain metastatic niche	80
Identification of specific PP2A complexes involved in human cell transformation	80
Selective inhibition of tumor microvascular permeability by cavtratin blocks tumor progression in mice	80
Increased antibody titers and reduced seronegativity following fourth mRNA COVID-19 vaccination in patients with cancer	79
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer	79
Vascular characterization reveals immunomodulatory targets for brain metastases	79
Spatiotemporal genomic profiling of intestinal metaplasia reveals clonal dynamics of gastric cancer progression	78

When immunotherapy meets surgery in non-small cell lung cancer	78
Revealing de novo pyrimidine synthesis as a key vulnerability in brain tumors	76
Eradicating micrometastases with immune checkpoint blockade: Strike while the iron is hot	76
The Terry Fox Research Institute Marathon of Hope Cancer Centres Network: A pan-Canadian precision oncology initiative	76
Infiltrating plasma cells maintain glioblastoma stem cells through IgG-Tumor binding	73
Nivolumab combined with induction chemotherapy and radiotherapy in nasopharyngeal carcinoma: A multicenter phase 2 PLATINUM trial	73
Genomic mapping of metastatic organotropism in lung adenocarcinoma	72
Molecular classification and diagnostics of upper urinary tract urothelial carcinoma	71
Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer	71
A druggable addiction to de novo pyrimidine biosynthesis in diffuse midline glioma	71
Epigenetic STING silencing is developmentally conserved in gliomas and can be rescued by methyltransferase inhibition	69
The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy	67
Overcoming melanoma therapy resistance with RAF-MEK and FAK inhibition	67
A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression	67
A proteogenomic surfaceome study identifies DLK1 as an immunotherapeutic target in neuroblastoma	66
Bridging the gap: The future of cancer research and clinical oncology in Cancer Cell	65
IL-6 blockade in cancer patients treated with immune checkpoint blockade: A win-win strategy	65
Sex and cancer immunotherapy: Current understanding and challenges	64
Understanding and reversing mammary tumor-driven reprogramming of myelopoiesis to reduce metastatic spread	64
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma	64
Mutations in IFN-γ signaling genes sensitize tumors to immune checkpoint blockade	64
Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer	63
Neutrophil-activating therapy for the treatment of cancer	62
Tim-4+ cavity-resident macrophages impair anti-tumor CD8+ T cell immunity	61
Enzyme-mediated depletion of methylthioadenosine restores T cell function in MTAP-deficient tumors and reverses immunotherapy resistance	60
Cancer-selective metabolic vulnerabilities in MYC-amplified medulloblastoma	60
Carnobacterium maltaromaticum boosts intestinal vitamin D production to suppress colorectal cancer in female mice	60
Immune phenotypic linkage between colorectal cancer and liver metastasis	59
Molecular subtypes of upper tract urothelial cancer: Setting the stage for precision therapy	59
T cell engagers in solid tumors kick the door down	58
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity	57
Insights into the co-evolution of epithelial cells and fibroblasts in the esophageal tumor microenvironment	57
A phenotypic signature that identifies neoantigen-reactive T cells in fresh human lung cancers	57
Simultaneous targeting of PD-1 and IL-2Rβγ with radiation therapy inhibits pancreatic cancer growth and metastasis	56
The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells	56
IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment	56
TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memory	55
Remodeling of the immune and stromal cell compartment by PD-1 blockade in mismatch repair-deficient colorectal cancer	55
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)	55
Senescent alveolar macrophages promote early-stage lung tumorigenesis	54
Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer	54
Cooperative CAR targeting to selectively eliminate AML and minimize escape	54
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy	53
Tailoring vascular phenotype through AAV therapy promotes anti-tumor immunity in glioma	53
Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts	53
Metabolic regulation of Cathepsin B in tumor macrophages drives their pro-metastatic function	53
The importance of ancestry to understanding tumor mutation burden in cancer	52
Tumor-reactive T helper cells in the context of vaccination against glioma	52
COVID-19 provides an opportunity to transform cancer research	52